Close

BioCryst Pharma (BCRX) Misses Q3 EPS by 3c

November 6, 2018 7:14 AM EST

BioCryst Pharma (NASDAQ: BCRX) reported Q3 EPS of ($0.28), $0.03 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $1.5 million versus the consensus estimate of $3.77 million.

For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

Earnings